
Design Therapeutics Inc
NASDAQ:DSGN

Intrinsic Value
The intrinsic value of one
DSGN
stock under the Base Case scenario is
4.32
USD.
Compared to the current market price of 3.68 USD,
Design Therapeutics Inc
is
Undervalued by 15%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Design Therapeutics Inc
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
Design Therapeutics Inc
Balance Sheet Decomposition
Design Therapeutics Inc
Current Assets | 234m |
Cash & Short-Term Investments | 229.7m |
Receivables | 1.4m |
Other Current Assets | 2.9m |
Non-Current Assets | 3m |
PP&E | 3.4m |
Other Non-Current Assets | -400k |
Free Cash Flow Analysis
Design Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Design Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-68m
USD
|
Operating Income
|
-68m
USD
|
Other Expenses
|
11m
USD
|
Net Income
|
-57m
USD
|
DSGN Profitability Score
Profitability Due Diligence
Design Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Score
Design Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
DSGN Solvency Score
Solvency Due Diligence
Design Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Design Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DSGN Price Targets Summary
Design Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
DSGN
is 7.48 USD
with a low forecast of 5.05 USD and a high forecast of 12.6 USD.
Dividends
Current shareholder yield for DSGN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
DSGN
stock under the Base Case scenario is
4.32
USD.
Compared to the current market price of 3.68 USD,
Design Therapeutics Inc
is
Undervalued by 15%.